Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | STAT1 | P42224 | 1/20 | 0.35 |
| ▸ | GRM6 | O15303 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | XBP1 | P17861 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4206559 | 0.89 | IGF1R (0.60) | IGF1RALDH1A1RAB9ALMNAPOLB | |
| SCHEMBL4203371 | 0.88 | IGF1R (0.56) | IGF1RALDH1A1RAB9ALMNAPOLB | |
| SCHEMBL4201253 | 0.88 | IGF1R (0.56) | IGF1RALDH1A1RAB9ALMNAMAPT | |
| SCHEMBL4198303 | 0.88 | IGF1R (0.56) | IGF1RALDH1A1RAB9ALMNAPOLB | |
| SCHEMBL4195862 | 0.87 | IGF1R (0.55) | IGF1RALDH1A1RAB9ALMNAPOLB | |
| SCHEMBL4200186 | 0.87 | IGF1R (0.52) | IGF1RALDH1A1RAB9ALMNAHPGD | |
| SCHEMBL4216016 | 0.86 | IGF1R (0.54) | IGF1RALDH1A1RAB9ALMNAPOLB | |
| SCHEMBL4210843 | 0.86 | IGF1R (0.51) | IGF1RALDH1A1RAB9ALMNAMAPT | |
| SCHEMBL4196034 | 0.85 | IGF1R (0.53) | IGF1RALDH1A1RAB9ALMNAGABRA1 | |
| SCHEMBL4207730 | 0.85 | IGF1R (0.58) | IGF1RALDH1A1RAB9ALMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538231-B2 | Tyrosine kinase inhibitors | MERCK & CO, INC. (US) | 2009-05-26 | — | — | US | claimed |
| EP-1651209-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2009-03-04 | — | — | EP | claimed |
| JP-2006528631-A | — | — | 2006-12-21 | — | — | JP | claimed |
| US-20060276514-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2006-12-07 | — | — | US | claimed |
| EP-1651209-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2006-05-03 | — | — | EP | claimed |
| WO-2005009373-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2005-02-03 | — | — | WO | claimed |
| US-7538231-B2 | Tyrosine kinase inhibitors | MERCK & CO, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7538231-B2 | Tyrosine kinase inhibitors | MERCK & CO, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7538231-B2 | Tyrosine kinase inhibitors | MERCK & CO, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| EP-1651209-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20060276514-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2006-12-07 | — | — | US | disclosed |
| EP-1651209-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005009373-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276514-A1 | Tyrosine kinase inhibitors | ABL1, RET, ERBB2 | IGF1R 102/4885ALDH1A1 2755/4885RAB9A 2642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.